Sugi Predict

Sugi Predict / Compounds / SCHEMBL21070780

SCHEMBL21070780

SCHEMBL21070780

CC(C)(C)OC(=O)N(CC(F)(F)F)c1cc(B2OC(C)(C)C(C)(C)O2)ccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 1/20 0.42
▸ BACE2 Q9Y5Z0 1/20 0.42
▸ USP30 Q70CQ3 2/20 0.39
▸ PRMT5 O14744 1/20 0.39
▸ WDR77 Q9BQA1 1/20 0.39
▸ AAK1 Q2M2I8 3/20 0.38
▸ DGAT1 O75907 1/20 0.36
▸ F2 P00734 2/20 0.35
▸ F11 P03951 2/20 0.35
▸ PRSS1 P07477 2/20 0.35
▸ PRSS2 P07478 2/20 0.35
▸ PRSS3 P35030 2/20 0.35
▸ HIF1A Q16665 3/20 0.35
▸ SSTR4 P31391 1/20 0.32
▸ ROCK1 Q13464 1/20 0.31
▸ HDAC1 Q13547 1/20 0.31
▸ HDAC8 Q9BY41 1/20 0.31
▸ HDAC6 Q9UBN7 1/20 0.31
▸ FFAR1 O14842 1/20 0.31
▸ GSK3A P49840 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26728111 0.88 BACE1 (0.42) BACE1BACE2USP30PRMT5WDR77
SCHEMBL21610948 0.87 F2 (0.41) BACE1BACE2PRMT5WDR77AAK1
SCHEMBL21672314 0.83 BACE1 (0.49) BACE1BACE2USP30PRMT5WDR77
SCHEMBL25146980 0.82 BACE1 (0.44) BACE1BACE2USP30PRMT5WDR77
SCHEMBL29845293 0.82 BACE1 (0.44) BACE1BACE2USP30PRMT5WDR77
SCHEMBL15074514 0.79 SSTR4 (0.39) AAK1F2SSTR4HDAC1HDAC8
SCHEMBL16703527 0.78 SSTR4 (0.41) AAK1F2SSTR4HDAC1HDAC8
SCHEMBL26380196 0.78 BACE1 (0.40) BACE1BACE2USP30PRMT5WDR77
SCHEMBL25992849 0.77 NR1H4 (0.39) BACE1BACE2
SCHEMBL31705720 0.76 BACE1 (0.40) BACE1BACE2USP30PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 — — US disclosed
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 — — EP disclosed
CN-113423427-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2021-09-21 — — CN disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
CN-112105385-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2020-12-18 — — CN disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 — — WO disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 BACE1 759/4885BACE2 749/4885USP30 148/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BACE1 759/4885BACE2 749/4885USP30 148/4885
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 BACE1 759/4885BACE2 749/4885USP30 148/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BACE1 759/4885BACE2 749/4885USP30 148/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BACE1 759/4885BACE2 749/4885USP30 148/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 BACE1 759/4885BACE2 749/4885USP30 148/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BACE1 759/4885BACE2 749/4885USP30 148/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 BACE1 759/4885BACE2 749/4885USP30 148/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BACE1 759/4885BACE2 749/4885USP30 148/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BACE1 759/4885BACE2 749/4885USP30 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.